



Intraocular Pressure Considerations

7

Yeni H. Yucel and Neeru Gupta

What Is Spaceflight-Associated Neuro-ocular Syndrome (SANS)?

The ability to see well is critical to the performance of all astronauts during spaceflight. The phenomenon of transient or persistent vision impairment in astronauts during space flight or following return to Earth has been recognized as a health risk that needs close attention [1]. This condition, coined as spaceflight-associated neuro-ocular syndrome (SANS) [2], consists of a cluster of pathological findings on eye examination including optic disc edema, retinal thickening around the optic disc, choroidal folds, retinal folds, and cotton wool spots [3]. A hyperopic shift is also observed [3]. To understand SANS, research programs have recently engaged in systematic ocular imaging studies to characterize and quantify changes in the eyes of astronauts. Optical coherence tomography (OCT) images show significant peripapillary retinal thickness increase and optic disc changes after spaceflight [4]. Recent studies reveal that retinal and choroidal changes in the eye occur early during spaceflight, persist throughout the mission, and require 45–90 days after returning to Earth to recover to preflight levels [5]. Furthermore, post-mission reductions in axial length of the eye and decreased anterior chamber depth have been noted and are likely to be associated with the observed hyperopic shift [5].

Fluid Shifts and SANS

Although the exact etiology of SANS is not yet known, microgravity-associated headward shift of intra- and extra-vascular fluids are implicated in this condition [6]. Optic disc edema is likely due to excessive interstitial fluid accumulation in the optic nerve head. Possible sources of this excess fluid include leaking capillaries of the optic nerve head [7, 8], and the peripapillary choroid [9] as they lack an effective blood–tissue barrier. Additional possible sources of fluid entry into the optic nerve head may be cerebrospinal fluid entry via optic nerve perivascular glymphatics [10]. The spread of excessive water from the optic disc into the surrounding retina may contribute to an increase in peripapillary retina thickness (Fig. 7.1). Other possible origins of excessive water entry into the peripapillary retina include the blood circulation via altered blood–retina barrier integrity [11], the vitreous via Muller cell aquaporin-4 [12], and the peripapillary choroid. The intraocular pressure (IOP) and the cerebrospinal fluid pressure (CSFp) would both be expected to influence the inner nerve fiber layer, the prelaminar and laminar parts of the optic nerve. We believe that fluid drained from the aqueous humor (AH) across neighboring vitreous [9, 13], and exiting across the retinal pigment epithelium [14, 15] to the richly vascularized choroid, may contribute to the retinal and choroidal

Y. H. Yucel (✉)

Departments of Ophthalmology and Vision Sciences and Laboratory Medicine and Pathobiology, Unity Health Toronto, St. Michael's Hospital, Temerty Faculty of Medicine, University of Toronto, Faculty of Engineering and Architectural Sciences, Physics, Faculty of Science, Toronto Metropolitan University Institute of Bioengineering, Science and Technology (iBEST), Toronto, ON, Canada
e-mail: yeni.yucel@unityhealth.to

N. Gupta

Departments of Ophthalmology and Vision Sciences and Laboratory Medicine and Pathobiology, Unity Health Toronto, St. Michael's Hospital, Temerty Faculty of Medicine, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
e-mail: neeru.gupta@unityhealth.to




Fig. 7.1 The headward shift of fluid under microgravity conditions (a) moves cerebrospinal fluid (b) (blue) from the subarachnoid space around the optic nerve into the optic nerve head and retina (orange) and

choroid (brown) via the glymphatic pathway (c) (blue arrows). The red arrows indicate the headward shift of fluid

changes. In addition to local hydrostatic pressure changes, this flow of fluid entry from the vitreous to the retina may be facilitated by a rise in oncotic pressure induced by plasma volume drops of 10%–15% while in flight [16].

Intraocular Pressure and SANS

Intraocular pressure (IOP) is a critical parameter to ocular function in health and disease states. It is a major risk factor for glaucoma, the leading cause of preventable irreversible vision loss projected to affect 111.8 million people by 2040 [17]. All treatments aim to lower IOP using a variety of pharmacological agents. The Ocular Hypertension Treatment Study showed that the incidence of glaucomatous damage increases with IOP [18]. Age greater than 40 years is also a risk factor for the development of both ocular hypertension and primary open-angle glaucoma, along with others such as myopia, ethnicity, and family history. Like any adult, it is recommended that all astronauts have regular eye examinations including IOP measurements and optic disc examination during and between spaceflights and post-retirement. Spaceflight-associated conditions including cardiovascular changes due to microgravity, hypercapnia, and low-grade radiation may be associated with IOP and glaucoma-like changes, and they should be taken into account with the above-listed risk factors. A critical review of the evidence regarding the role of IOP in the development of SANS is timely as private space companies (e.g., SpaceX, Blue

Origin) aim to increase accessibility to spaceflight for civilian populations [19–21] with demographic and health characteristics that are different from those of astronauts.

The shape of the outer corneal-scleral shell is maintained by IOP which is finely regulated to prevent ocular hypertension and hypotony and vision-threatening conditions that arise due to swings in eye pressure. The light path to the retina depends upon optical characteristics of the cornea, AH, pupil, lens, and vitreous, all of which are also highly dependent on the IOP. The light-sensitive retina sits on the choroid, a pigmented and highly vascularized layer, supported by the underlying sclera which is an opaque and fibrous outer layer. Their shape and integrity also depend upon IOP. Various parameters such as the axial length between the cornea and retina, in addition to anterior chamber depth, can be altered during disturbances of globe shape. As IOP depends on both ocular hydrodynamics and hemodynamics, its measurements can inform us about both of these highly regulated systems. Although changes in IOP are not included in the definition of SANS, IOP and its hydro- and hemodynamics-determinants are fundamentally relevant to our understanding and prevention of this sight-threatening condition. Here we will review and tie together observations of IOP changes during and after spaceflight, discuss methods to measure IOP, and re-iterate the role of IOP as a physiological parameter that should be monitored as part of eye changes in SANS. This approach will guide studies on the efficacy and safety of SANS countermeasures.

IOP Conceptual Model: Ocular Pressure–Volume

Several conceptual models can contribute to our understanding of IOP. In the ocular pressure–volume model, IOP is an exponential function of the total ocular volume (V_t) and the elasticity (E) of the corneal-scleral shell ($IOP = (V_t, E)$)—the theoretical basis for indentation tonometry and tonography [22]. Another model treats steady-state IOP as a function of aqueous flow (F), outflow conductance (C), or “facility” and episcleral vein pressure (EVP) [23]. This model ($IOP = F/C + EVP$) is the theoretical basis for understanding ocular hypertension and hypotony as well as current medical and surgical treatment to lower IOP to treat glaucoma. Both models provide insight into IOP physiology [24].

Aqueous humor and vitreous fluid, and uveal blood, especially choroidal blood are the main compartments generating IOP in “normal gravity” or 1g conditions (Fig. 7.2).




Fig. 7.2 Schematic of ocular hemodynamic and aqueous humor and vitreous fluid compartments generating IOP. Extraocular and intraocular arteries are represented in red, with extraocular and intraocular veins in blue. The uveal (ciliary body and choroid) blood compartment is represented by a red/blue rectangle. The combined aqueous humor and vitreous fluid compartment is represented in yellow. Trabecular and uveoscleral outflow pathways from the anterior chamber are indicated by black arrows. Trabecular outflow drains into episcleral veins (small blue). Lymphatic vessels in green drain fluid from the intraocular and extraocular interstitial tissue (white background). Figure adapted from Kiel et al. (2010) [24] and Watenpaugh and Hargens (1996) [25]

Aqueous Humor Dynamics and Regulation of IOP (Fig. 7.2)

AH hydrodynamics determine the quality of AH, its chemical composition, electrolyte balance, and pH. Circulating AH supplies oxygen and nutrients to the avascular tissues of the anterior segment such as the cornea, trabecular meshwork, and lens and subsequently removes metabolic waste products. Although difficult to measure with currently available techniques, some AH drains into the vitreous cavity [26] and provides regular water content to the vitreous. Compared to the plasma, the aqueous has a low protein level (about 0.02 g/ml compared to 7 g/ml) [27]. Briefly, AH secreted by the ciliary epithelium into the posterior chamber (also called AH inflow), passes between the anterior surface of the lens and posterior surface of the iris into the anterior chamber. The AH drains from the anterior chamber through several routes (also called AH outflow) [26, 28]. AH flows out of the eye either through the trabecular meshwork, eventually reaching the systemic blood circulation via the episcleral veins [29–31], or through the ciliary body into suprachoroidal spaces, and sclera via the uveoscleral route [32]. A growing body of evidence shows drainage of AH from the eye also via lymphatics [33, 34], with lymphatic channels in the human ciliary body identified using molecular markers [33]. Methods to measure the AH dynamics parameters including aqueous production, trabecular outflow, EVP, uveoscleral outflow [26], and lymphatic drainage [34] are available. The development of novel dynamic non-invasive techniques to assess specific outflow pathways to determine the drivers of intraocular pressure and their relative contributions will guide individualized care.

All currently used IOP-lowering glaucoma eye drops target aqueous inflow and/or outflow pathways. Common IOP-lowering pharmacological agents either reduce aqueous inflow by action on beta-adrenergic receptors and carbonic anhydrase inhibitors or increase outflow via their action on α_2 adrenergic receptors of the autonomic sympathetic system, prostaglandin $F_{2\alpha}$ receptors, and inhibition of Rho kinase [35].

Some aqueous outflow structures such as the trabecular meshwork, canal of Schlemm and episcleral vein; in addition to playing a filtering role, participate in cardiac-induced pulsatile aqueous outflow mechanisms with systolic expansion of the choroid [31]. Thickening of the choroid during spaceflight may cause reduced cardiac pulsatility-induced AH outflow, in addition to IOP increase due to increased volume effect.

Unlike increased IOP, low pressure in the eye known as ocular hypotony, especially after long-term or multiple missions has often been overlooked as a potential risk factor. Although the clinical signs and symptoms of ocular hypotony are usually reversible in acute and transient stages, chronically decreased IOP can have deleterious effects on intraocular tissue morphology and function [36–38]. An imbalance of aqueous production and outflow (trabecular, uveoscleral) after return to Earth after a long-duration mission may contribute to alterations of aqueous flow dynamics. These may be associated with compromised oxygen supply, nutrition, and metabolic exchange within the anterior chamber, and water content to vitreous, leading to ocular hypotony with complications of retinal [39] and choroidal folds, detachment [37, 40–42], and posterior pole and scleral flattening [43]. Close follow-up of IOP is required after landing to rule out prolonged ocular hypotension. Unfortunately, treatment options to manage ocular hypotony are limited.

IOP in Relation to Ocular Volume

If corneal-scleral elasticity is constant, acute changes in IOP must involve changes in ocular volume. AH and ocular blood volume changes are the most labile and are responsible for the greater part of IOP variation (Fig. 7.3). Uveal blood, especially choroidal blood and aqueous humor and vitreous fluid are the main compartments generating IOP in 1 G conditions (Fig. 7.3a). In this model, we have combined aqueous humor with vitreous given that the AH provides water content to the vitreous body [26]. In early microgravity, due to a headward shift of fluid, the volume of intraocular blood increases, leading to IOP elevation (Fig. 7.3b). During adaptation to microgravity, aqueous humor volume decreases with normalization of IOP (Fig. 7.3c).

During early space flight under microgravity conditions, there is an increase in uveal volume (ciliary and choroid) induced by congested blood vessels (Fig. 7.3b). There is also increased aqueous production and decreased trabecular outflow due to elevated EVP. Reduced uveoscleral outflow and lymphatic drainage would contribute to elevated IOP. Aqueous volume changes may occur with transient imbalances in aqueous production and outflow. Similarly, ocular blood volume changes may occur with blood flow imbalance into and out of the eye, especially at the level of the choroid [44], as evidenced by increased choroidal thickness observed in astronauts during spaceflight [5].

A decrease in aqueous production, with simultaneous increases in trabecular, uveoscleral and lymphatic drainage, would reduce aqueous and vitreous volume allowing a return to baseline IOP.

In early landing, uveal blood (Fig. 7.4a) volume decreases compared to adapted microgravity (Fig. 7.4b) with an IOP decrease. In late landing, the aqueous humor/vitreous volume is restituted with normalization of IOP (Fig. 7.4c). In landing, a decrease in volume of the uvea (ciliary and choroid), relative increase in trabecular outflow due to decreased EPV, and increased uveoscleral outflow with lymphatic flow would contribute to IOP lowering. A delayed increase in aqueous production with decreases in trabecular outflow, uveoscleral outflow and lymphatic flow would contribute to a return to baseline IOP. For individualized countermeasures and treatment, it would be critical to monitor specific components of AH dynamics and ocular hemodynamics.

Neurohumoral and local control mechanisms involved in the regulation of the resistance at the level of ciliary and choroidal vasculature are not fully understood. Autoregulatory myogenic [45] and autonomic neural mechanisms [46, 47] regulate ocular blood volume during changes in arterial pres-




Fig. 7.3 Schematic of main ocular compartments generating IOP in Earth, Early in Space, and Adaptation in Space. Uveal blood, especially uveal blood (red), and aqueous humor and vitreous fluid (yellow) of the eye in 1g conditions. During early spaceflight under microgravity con-

ditions, the volume of uveal blood increases due to a headward fluid shift. While in space, adaptation involves a decrease in aqueous humor/vitreous volume




Fig. 7.4 Ocular compartments in transition to landing: Uveal blood (red), and aqueous humor and vitreous fluid (yellow) of the eye in adapted in space. In early landing the uveal blood component volume decreases. In late landing, the aqueous humor/vitreous volume increases

sure [45]. While increases in arterial pressure produce initial increases in IOP (Fig. 7.3b), this IOP elevation is not sustained. Instead, early elevated IOP increases the pressure gradient for aqueous outflow, causing a compensatory decrease of aqueous and vitreous volume so that IOP gradually returns to baseline (Fig. 7.3c) [45]. If the increase in blood volume is small, the compensation is relatively quick, whereas compensation for a larger increase in blood volume, takes longer. IOP falls below baseline when arterial pressure-induced distention of the vasculature is abruptly ended in early landing (Fig. 7.4b). This reflects a compensatory loss of aqueous and vitreous volume, which is gradually restored by continued aqueous production, until a return to baseline IOP (Fig. 7.4c). Raising arterial pressure elicits a modest increase in IOP under control conditions. A much larger increase is elicited when choroidal blood volume regulation is impaired by systemic vasodilation by pharmacological tools [45], by altered autoregulatory myogenic [45], autonomic neural mechanisms [46, 47], and neuro- and endocrine mechanisms. Thus, ocular blood volume changes are strong influencers of IOP. Ocular blood volume changes are compensated by corresponding changes in AH and vitreous volumes which contribute to the IOP regulation.

IOP and Postural Changes

Postural changes are known to affect IOP with significant increases in IOP from the upright or sitting position to the supine position [48–50]. IOP has been shown to increase by 3–4 mmHg in normal subjects when lying supine, regardless of the time of the day [51, 52]. EVP is the only component of

AH dynamics that is affected by body position, increasing by 3.6 mmHg from the seated to supine position. Mean IOP and mean EVP increase significantly from the sitting to the inclined position [53]. In contrast, the rate of AH formation is stable while subjects are alternated between an upright and inverted body position [54]. No changes to outflow facility are noted between sitting and supine positions [55].

IOP and Ocular Perfusion Pressure

Ocular perfusion pressure (OPP), calculated by the mean arterial pressure (MAP) minus the IOP [56], is an important parameter to assess tissue perfusion. To avoid the collapse of intraocular veins, IOP should remain below venous pressure within the eye. If IOP is higher than MAP, the perfusion of tissues fed by intraocular arteries will be reduced. Blood flow to the inner retina and optic nerve head by branches of the central retinal artery is mainly modulated by local autoregulation according to local metabolic demands as in other parts of the central nervous system. The outer and avascular portions of the retina receive nutrients and oxygen via diffusion from the choroidal blood vessels that do not receive feedback signals from the retina. The sympathetic and parasympathetic components of the autonomic nervous system substantially influence numerous ocular functions including ocular blood flow [47]. As postural IOP changes are larger in patients with autonomic failure compared with normal subjects [57], suggesting that the autonomic nervous system plays an important role in regulating IOP during postural changes. Continuous and simultaneous measurements of IOP and local mean arterial pressure (MAP) would be opti-

mal to monitor OPP during postural changes over time, during day and night cycles, and in microgravity conditions.

IOP, CSFp, and Translaminar Pressure Difference (TLPD)

Under normal physiologic conditions, the TLPD, the difference between IOP and the retrolaminar CSF, generates both a net posterior force on the surface of the LC and a hydrostatic pressure gradient within the prelaminar and laminar optic nerve. In glaucoma, pathology occurs at the level of the LC [58], and the TLPD has been proposed to be involved in its pathogenesis [59]. In addition, TLPD may be involved in conditions in which edema of the optic disc is prominent as in idiopathic intracranial hypertension, and obstructive hydrocephalus [60]. In vivo measurement of pressure directly around the LC is currently not feasible, proxies of the pressure in regions anterior and posterior to the LC, are IOP measured at the cornea and CSFp measured by lumbar puncture (LP), respectively. A limitation of these proxies to calculate TLPD is the difference in body position at which the measurements are taken. For example, Goldmann applanation tonometry is commonly carried out in the seated position while LP is performed in the lateral decubitus position. As both IOP and CSFp change with posture, measuring them in different conditions to calculate TLPD is problematic. TLPD in healthy controls is 1.4 mmHg when measuring IOP in the sitting position and the CSFp via LP in the lateral decubitus position [61]. However, a recent study in healthy subjects demonstrates that both CSFp and IOP change during postural changes. TLPD differences of 19.8 mmHg while seated, 12.3 mmHg while supine, and 6.6 mmHg while in the 9° head-down tilt position have been shown [62]. A limitation of this estimation is the assumption that CSFp at the lumbar level is similar to CSFp at the perioptic subarachnoid space. In addition, TLPD depends on LC thickness and its reduction in highly myopic eyes may be the histologic correlate of increased susceptibility to pressure-induced injury [63].

Continuous, simultaneous, and direct measurements of IOP and CSFp in nonhuman primates have shown that TLPD changes significantly and instantaneously from the supine to seated (+14 mmHg), supine to standing (+13 mmHg), and supine to inverted (−12 mmHg) positions. No significant TLPD change from the supine to prone positions is noted. CSFp showed greater relative change than IOP [64]. The 56% increase in TLPD during waking hours in nonhuman primates [65] was reported to match the increase in TLPD due to postural change from supine to upright in humans [62].

Orbital Pressure and IOP

The orbital soft tissue surrounding the globe is confined by the bony orbital socket and semi-rigid fascia-like tissue of the eyelid anteriorly. Most orbital blood vessels are tributaries of intracranial blood vessels, and are in direct contact with ocular blood vessels, and share similar autonomic control [66, 67]. They are also connected to extracranial blood vessels via anastomoses [68].

Orbital conditions including vascular malformation such as Sturge-Weber syndrome, orbital tumors, and endocrine orbitopathy can cause congestion of the orbital veins and a subsequent rise in EPV [69]. Large vessel venous obstruction (superior vena cava syndrome), cavernous sinus thrombosis, and carotid cavernous sinus fistulas can cause an increase in superior ophthalmic vein pressure and a rise in EVP [70]. Sturge-Weber syndrome in older children and young adults with port-wine stains (hemangiomas) on the face near the eye can include intrascleral or episcleral anastomoses that increase EVP [71] and in turn, IOP [72, 73]. Some of these conditions may also be associated with increased choroidal thickness [74–76]. Further volumetric imaging studies of the orbital tissue components, intra- and extravascular fluids in and around the globe, and CNS, are needed to understand changes in SANS [77]. Lymphatics in the orbit [78] are implicated in the drainage of fluid from the orbit and contribute to lymphatic drainage from the eye [35] and perioptic subarachnoid space [79] (Fig. 7.5).




Fig. 7.5 Schematic of the globe and orbit with lymphatics draining excess fluid into regional lymph nodes (green) on Earth (left) and in space (right). Under microgravity conditions in space, lymphatic drainage from the optic nerve and the eye is reduced with fluid accumulation in the optic nerve and retina (orange), and choroid (brown). Extraocular muscles and orbital soft tissue are presented in red and gray, respectively. Black arrows represent lymphatic flow. The black arrow with dotted line represents decreased lymphatic flow in microgravity. The orbital bony socket is represented in white superiorly

Autonomic and Central Regulation of IOP

The autonomic nervous system (ANS) serves as an important interface between body, central nervous system (CNS), and external stimuli [80–82]. The ANS sympathetic noradrenergic system (SNS), parasympathetic cholinergic system (PCS), and sympathetic adrenergic system (SAS) together control visceral functions to maintain homeostasis. The SNS and PCS play key roles in regulating optimal cardiovascular function to maintain the physiological state of astronauts despite the stressors of spaceflight [83]. The role of the autonomic system in the regulation of IOP is complex, acting on both AH dynamics and ocular hemodynamics. Evidence for autonomic sympathetic and parasympathetic innervation of the anterior episcleral circulation comes from histological studies in primates [84] of trabecular meshwork and scleral spur [85]. In rodents, electrical stimulation of the superior salivatory nucleus elicits an increase in IOP and EVP [86] and choroidal vasodilation [87]. Changes in choroidal thickness due to vascular congestion during the flight [5] may contribute to altered thermal environment in the central retina [88, 89], especially when central body temperature is increased during spaceflight [90]. The action of topical adrenaline or epinephrine on the IOP, aqueous humor dynamics and ocular hemodynamics has been studied [91–94], however the role of adrenaline as a neurohormone of the sympathetic adrenergic system on the eye's physiology is not well elucidated.

Both sympathetic and parasympathetic systems are involved in the regulation of the systemic lymphatic system [95], implicating them in lymphatic drainage from the eye, orbit, and cerebrospinal fluid.

Mechanisms of central regulation of AH dynamics are underexplored. Early experiments in primates show that intracranial hypertension induced by inflation of an epidural balloon leads to an increase in IOP [96]. A recent study in rats demonstrated that a neural feedback mechanism driven by ICP regulates conventional outflow facility that leads to IOP increase [97]. Experimental studies have demonstrated the impact of the hypothalamo-pituitary-suprarenal system in the regulation of IOP [98–100]. Delivery of hypo-osmotic agents into the third ventricle resulted in IOP elevation, while the delivery of hyperosmotic agents lowered IOP [101]. Third ventricle injection of substance P [102], thyrotropin-releasing hormone (TRH) [103], or arginine vasopressin [103] also elevated IOP. Injection of a GABA(A) receptor antagonist bicuculline into the dorsomedial and perifornical hypothalamus in rats increased IOP [100].

Circadian Changes

In the general population, IOP ranges between 10 and 20 mmHg with an average of 15.5 mmHg. IOP is a dynamic parameter with distinct circadian rhythms and spontaneous variations [104]. Diurnal variation for normal eyes is between 3 and 6 mmHg. IOP undergoes nocturnal elevation due to circadian rhythm, independent of posture changes [50, 105–107] and variations of 24-h IOP in the right and left eyes are similar [108].

AH flow also demonstrates a circadian rhythm with a peak in the morning and at night [109, 110]. The role of the central circadian clock via melatonin and the possible role of the ocular circadian clock are active areas of research [111]. Recent studies in mice suggest that IOP rhythm entrainment is mediated by a systemic rather than local signal [112] and that intact adrenal function [113], glucocorticoids, and the sympathetic system [114] are required for manifest circadian rhythms of IOP. At this time, it is unknown whether circadian rhythm changes observed in spaceflight [115, 116] contribute to IOP changes.

IOP Changes in Space

Given the immediate increase in IOP noted upon entering weightlessness, studies of IOP are of great interest. The first inflight IOP readings performed during a D1 Spacelab mission showed a rise of 20–25% in IOP 44 min after entry to microgravity conditions [117]. A subsequent study documented a 92% increase in IOP after 16 min entry in microgravity (German–Russian MIR mission) [118]. A 114% increase in IOP was reported during a D2 Spacelab mission [119]. Furthermore, data acquired on the first day of six different space shuttle missions for 11 subjects revealed an increase of 4–7 mmHg [120]. While IOP has been reported to return to baseline values within the first week of microgravity exposure [118–120], a mean IOP rise of 26.3% in a woman astronaut was still present at day 8 during spaceflight [121]. Thus, currently published data suggest that IOP increases upon entering weightlessness [118, 119]. Chronically elevated IOP has not been observed in astronauts during long-duration ISS missions. Tonometry data from the Lifetime Surveillance of Astronaut Health study of 15 subjects suggested no change in IOP on day 30 in flight, and 30 days prior to return to Earth compared to pre- or postflight. The IOP among subjects with optic disc edema on fundoscopy upon

return to Earth did not differ from remaining crew members [121]. After return from long-duration spaceflight, IOP values were similar to preflight measures (10–14 mmHg vs. 10–16 mmHg, respectively) [3]. IOP measured after landing on Earth may be lower than preflight levels as suggested by postflight decrease of IOP compared with preflight measurements observed in Apollo astronauts [123].

Despite the sustained headward fluid shift and cardiovascular changes during the first few days of spaceflight, the immediate IOP increase followed by a return to baseline within the first week suggests compensatory mechanisms that are not yet fully elucidated. If we assume this early IOP increase is due to headward fluid shift and cardiovascular adaptation leading to an increased intravascular volume, especially in the uvea, the compensatory mechanisms may relate to aqueous inflow and outflow changes that decrease AH volume. Understanding these compensatory mechanisms are important to understanding the long-term effect of these changes.

During long-duration missions, cardiovascular changes of decreased mean arterial pressure (MAP) and increased cardiac output (CO), indicate a lower systemic vascular resistance (MAP/CO) [124]. These changes alter ocular blood volume and exert influence on IOP. Neurohormonal changes implicated in the cardiovascular adaptive process may also influence both ocular hemodynamics and hydrodynamics. Thus, IOP changes are an integral part of the development and progression of ocular changes during flight, and recovery after landing. While determinants of IOP such as ocular hydro- and hemodynamics in the development and progression of SANS remain relatively unexplored, IOP is an important parameter to include in future studies to understand, prevent and treat SANS.

IOP decrease below baseline after landing may also be explained by a decrease in choroidal vascular congestion and delayed recovery of decreased aqueous volume by changes in aqueous inflow and outflow. Measurements of episcleral pressure changes, and outflow facility performed after landing can help to understand these compensatory changes.

IOP is a dynamic parameter with many influences, with distinct circadian rhythms, and spontaneous variations [104]. Its measurement depends on the devices used to evaluate IOP before, during, and after flight. In addition, the training of operator with the device, time of the day, body position,

are critical to insights into IOP elevation. In most IOP studies in astronauts, details regarding IOP measurement methodology are lacking. Future studies should disclose this important information per subject rather than reporting only group differences. Long-term spaceflight-induced IOP changes may be in the order of a few mmHg, so more sensitive IOP measuring devices can better assess IOP changes.

Elevated CSFp was previously believed to be related to SANS given the swollen optic disc appearance of papilledema and optic nerve edema observed [125, 126]. The observation that CSFp does not go up under microgravity conditions has questioned the role of high CSFp in astronauts [127]. There is no evidence of sustained IOP increase [3, 117, 128] or decreased CSFp. Carefully designed studies with simultaneous IOP and CSFp measurements will allow correlation of their changes with retinal, optic nerve, and choroidal changes observed by ocular imaging during and after flight.

In addition to microgravity, other extreme conditions such as hypercapnia [129, 130] and various type of exercise regimes [131–144] likely contribute to IOP changes during flight and to SANS development. Whether chronic low-dose radiation exposure is associated with IOP changes and SANS also need to be studied.

Countermeasures such as exercise with or without the Advanced Resistive Exercise Device (ARED) and Lower Body Negative Pressure (LBNP) suit are used to mitigate microgravity-induced bone loss, muscle atrophy, and cardiac deconditioning [145].

The effects countermeasures on IOP and SANS are not yet known. Studies in experimental models and on-ground analogs that mimic microgravity conditions will help to unravel the relationship involved in changes of IOP to SANS and the efficacy and safety of countermeasures.

IOP in Microgravity Models

Ground-Based Analogs

As space missions are costly and low in number, human studies in ground analogs are good alternatives for gravitational research that can complement and inform research studies in space [146]. The main ground-based analogs are head-down tilt bed rest and dry immersion.

Head-Down Tilt (HDT) Bed Rest

HDT bed rest is the most common ground-based model used to study the physiological effects of microgravity on the cardiovascular and musculoskeletal systems [147]. The HDT bed rest mimics cephalic fluid shift, immobilization, confinement, and inactivity. The subject remains in the supine position at -6 degrees HDT bed rest for either short periods (from 1 week to 1 month) or sometimes longer periods (>1 month). HDT bed rest may be used to understand eye changes during headward fluid shift. Subjects who underwent 70-day -6° HDT bed rest showed an increase in OCT peripapillary retinal nerve thickening [148], unlike subjects who underwent 4.5-h-HDT at -6° , -12° , and -18° tilt angles or 14-day exposure to -6° HDT bed rest [149]. Healthy subjects undergoing strict HDT bed rest showed a larger increase in peripapillary total retinal thickness compared to 20 astronauts during ~ 30 days in spaceflight [150]. Interestingly, choroid thickness shows a larger increase in astronauts compared to the strict HDT bed rest subjects.

-6° HDT bed rest studies have shown inconsistent findings regarding IOP. Early studies showed normalization or lower IOP within 5–6 days [151], while more recently, an increase of 2 mmHg after 10 days has been reported [149]. One -6° HDT study of 14- and 70-days observed an increase in IOP with +1.42 and +1.79 mmHg from baseline, respectively. Systematic comparisons of spaceflight IOP data and HDT bed rest studies with close attention to IOP measuring device, body position and time of the day, are needed. The sympathetic system is decreased in HDT bed rest and not in spaceflight [152], suggesting differences that should also be considered.

HDT bed rest studies may also help to study possible risk factors for SANS such as myopia [153], and its effect on the water content in the vitreous using MRI [154].

Dry Immersion

In the dry immersion model of microgravity, the subject remains immersed in thermoneutral water covered with an elastic waterproof fabric, isolating the subject from the water. Thus, the subject floats freely while remaining dry. One of the main features of dry immersion is that it imitates the absence of any supporting structure for the body, centralization of body fluids, immobilization, and hypokinesia observed during spaceflight [155]. Dry immersion rapidly induces a wide range of physiological effects of weightless-

ness including cardiovascular alterations [156] associated with sympathoexcitation [157] and possible effect on intracranial pressure (ICP) effects [158]. During 5-day dry immersion experiments, although IOP did not differ from baseline in the healthy eye, intraocular fluid production rate (F) was decreased in 60% of cases by day 1 [159].

Ground-based analogs such as HDT bed rest and dry immersion represent an opportunity to better understand IOP with rigorous IOP measurement technologies.

Countermeasures

Exercise

To mitigate muscle atrophy due to microgravity, astronauts undergo 2.5 h of intensive resistance and aerobic exercise nearly every day onboard the ISS [160].

Short-term exercise overall has an IOP-lowering effect [161]. Dynamic exercise has a greater IOP-lowering effect than isometric exercise [133], and the IOP-lowering effect of exercise increases with its intensity [134, 135]. Anaerobic exercise also seems to decrease IOP [136, 137]. With strenuous exercise, it appears that IOP is inversely related to plasma osmolarity during and after strenuous exercise [137]. Dehydration during strenuous exercise and elevated colloid osmotic pressure significantly reduced IOP compared with hydrated subjects with normal colloid osmotic pressure [162].

Although choroidal blood flow increases somewhat in the immediate post-exercise period [163], it is not yet known whether exercise-induced choroidal changes contribute to IOP changes during and after exercise.

Certain types of exercises such as weightlifting or exercise at maximal exertion can increase IOP. One study compared weightlifting with and without subjects holding their breath and found that IOP increased more prominently when the subject hold their breath [142]. Another study concluded that elevated ICP reduces ocular venous outflow in weightlifting subjects who are essentially performing a Valsalva maneuver, contributing to raise in IOP [143]. During maximal exertion, subjects are essentially performing a Valsalva maneuver known to increase IOP in the absence of other factors [144].

NASA's integrated resistance and aerobic training during a 70-day non-hypercapnia strict -6° HDT bed rest protocol was not associated with a significant difference in retinal thickening or signs of optic disc edema compared to a con-

trol HDT bed rest group though IOP was slightly higher in the exercise group [164]. Interestingly, -15° HBT bed rest for less than an hour was associated with a decrease in IOP in subjects undergoing either moderate-intensity aerobic, resistance or high-intensity interval aerobic exercise [165]. These differences highlight the impact of countermeasures that depends on duration and tilt angle of HDT bed rest. Integrating results from different HDT bed rest models is needed to better understand the short- and long-term effects of countermeasures.

Astronauts follow a rigorous exercise regime [160], so it is important to consider the effect of exercise in subjects who undergo regular exercise programs. A regular exercise program lowers baseline IOP, and diminishes acute decreases in IOP in the post-exercise period [140, 141, 166]. Exercise regimes may differ in type and intensity which may alter baseline IOP and their relative risk profile. IOP measurement before, during, and after spaceflight should consider time of the day in relation to exercise and should report individual data rather than strictly between groups, compared to the age-matched general population.

Lower Body Negative Pressure (LBNP)

LBNP using the Chibis Suit is commonly used by cosmonauts to counteract cephalic fluid shifts [167]. This countermeasure mitigates headward fluid shift, attenuating ocular changes (choroidal engorgement) associated with cephalad fluid shifts seen in HDT bed rest [168–170]. 15° head-down tilt increases IOP, while application of LBNP significantly reduces IOP [52]. The effect of LBNP on IOP during -6° HDT bed rest for longer periods is not yet known.

Artificial Gravity

Exposure to artificial gravity (AG) either continuously or intermittently simulates gravitational states on board the spacecraft. Enhancing adaptation during the mission to Mars gravity and re-adaptation to Earth [171], AG offers a countermeasure with the potential to address bone loss, cardiovascular deconditioning, and muscle weakening [172, 173]. AG is considered an integrated countermeasure because it addresses all of these systems [174] and can be combined with other countermeasures [172]. AG has been proposed as a potential countermeasure for SANS [171]. IOP increases observed in the supine position remained elevated under AG conditions in healthy volunteers [175].

Animal Models

Experimental animal studies both in space and on the ground may help us to better understand the role of IOP and the determinants of AH dynamics and ocular hemodynamics.

Animal Experiments in Space

Recent studies in mice on ISS at the Japan Aerospace Exploration Agency's mouse housing unit [176] demonstrated molecules involved in the regulation of intraocular fluids and of the blood–retina barrier. Immunohistochemical analysis of the retina revealed increased expression of aquaporin-4, a water channel mainly seen in the CNS, as a strong indication of altered blood–retina barrier integrity after spaceflight compared to controls. There was also a significant increase in the expression of platelet endothelial cell adhesion molecule-1 (PECAM-1) and a decrease in the expression of the BRB-related tight junction protein and Zonula occludens-1 (ZO-1) after spaceflight [11]. It is interesting to note that aquaporin-4 is implicated in the outflow of water from the vitreous into the retina [12].

Animal Ground Models

Nonhuman primates have been used in spaceflight to understand microgravity effects [177], and are also used in biomedical research to study IOP and AH dynamics-related h, based on their similarities with humans [178–181]. The nonhuman primate model has been used for continuous monitoring of IOP and ICP to evaluate posture-related IOP changes [64, 65]. Head-out water immersion experiments in primates show some similarities to cardiovascular deconditioning [182]. Similarities to man regarding CNS and CSF dynamics, eye and brain anatomy and physiology [179–181] make the non-human primate model may also be adaptable to study SANS with capacity to develop and validate of new non-invasive IOP measuring technology that can be used during spaceflight.

An experimental ground model of hindlimb unloading in rodents that mimics microgravity conditions has been developed by NASA to study bone loss, muscle atrophy, and cardiovascular changes observed in astronauts [183, 184]. Changes in gravitational forces and central venous pressure likely alter passive lymphatic flow [185, 186], and there is evidence that the active pump of cervical lymphatic vessels is inhibited [185]. The mouse model shows similar AH dynamics to men [187] and its small size has multiple advantages for biomedical science [188]. The mouse hindlimb

unloading model may be adapted to study eye changes induced by headward fluid shift and to study the interplay between the eye, cardiovascular system, and central nervous system. Recent studies show CSF entry into the optic nerve along small perforating pial vessels through sleeve-like paravascular spaces between vessel walls and aquaporin-4-positive astrocytic endfeet [10]. AH drains into cervical lymph nodes [35, 189], and these coincide with those into which CSF is also drained [190, 191]. Non-invasive *in vivo* quantitative techniques in mice [192, 193] and studies of these elusive fluid pathways in hindlimb unloading experiments may help to inform otherwise more expensive studies on Earth and in space.

Non-invasive IOP Measurement and Devices

Tonometry is used to measure IOP based on the relationship between the IOP and the force necessary to deform the cornea by a given amount. Several types of tonometers are used during spaceflight and in-ground analog experiments. Some are slit-lamp mounted devices, while others are portable. While a comprehensive review of tonometers is beyond the scope of this chapter, the main instruments been used on astronauts are highlighted below.

Goldman applanation tonometry (GAT) has been the standard in clinical practice for the measurement of IOP. It is, however, largely influenced by ocular properties and variations in corneal biomechanics [194]; it is subjective and prone to learning; its use outside clinical settings is limited by the need for topical anesthetic, fluorescein, and a slit-lamp microscope to perform measurements. The portable version of this is the Perkins tonometer. A portable applanation self-tonometer specifically designed for spaceflight used by Draeger and coworkers is based on an automatic measuring procedure and an optical sensor that replaces the eye of an examiner [128].

The Tono-pen is a handheld portable tonometer that determines IOP by making contact with the cornea by way of a probe tip, causing applanation/indentation of a small area. Topical anesthesia eye drops are used. After four valid readings are obtained, the average measurement is given together with the standard error. Some studies have reported that the Tono-Pen underestimates postural IOP responses [51, 195–197], while other studies do not during spaceflight [121].

Rebound tonometry (RT) (iCare, Tiolat, Helsinki, Finland) is portable and easy to use. Although it is a contact tonometer, topical anesthesia drops are not required and the tonometer has a disposable tip to minimize cross-infection. The device processes the rebound movement of a rod probe

resulting from its interaction with the eye; rebound increases (shorter duration of impact) as the IOP increases. Six measurements are taken and their average is displayed. RT shows high reproducibility and less dependency on ocular characteristics [198–200]. RT has been used in a 7-day-HDT best rest study [151].

The TON-1 compact eye tonometer-tonograph in an impression tonometric method. The device is designed for easy and rapid measurements of true IOP, and quantitative monitoring of intraocular fluid and blood in the eye, and calculates tonometric, tonographic, and sphygmographic characteristics [201]. The TON-1 was used in a 5-day dry immersion experiment [159].

A pressure phosphene tonometer that is applied to the eye with closed eyelids has also been used during spaceflight [122]. It was reported that phosphene tonometer measurements may be influenced by eyelid skin edema due to fluid shifts [122].

Dynamic contour tonometry (DCT, or Pascal) is a slit-lamp mounted and contact IOP measurement device that may present some advantages. It contains a sensor tip with concave surface contour and a miniaturized pressure sensor. The results and quality score measures are provided digitally. DCT is considered an accurate technique [202], and is less influenced by central corneal thickness compared with GAT [203–205]. Additionally, it measures the ocular pulse amplitude which is the difference between the mean systolic and diastolic IOP. These characteristics may present some advantages for ground analog experiments.

Tonometry data is collected as part of medical testing requirements for astronauts, GAT mounted on a slit-lamp, measures pre- and postflight on subjects while seated, and the handheld Tono-pen is used by crew members on each other during spaceflight [121]. Understanding the principles, advantages, and limitations of various IOP measuring devices and effects of different contexts before, during, and after flight or in ground analog experiments is an important area of future research. Low-mass, low-volume devices that can be used during flight requiring to allow self-IOP assessment, or use by another astronaut, are important considerations.

IOP measurements during space flight are based on the assumption that the compliance of the cornea and sclera remain unchanged. However, it is not yet known whether biomechanical properties of cornea and sclera may also change. Rich in glycosaminoglycans [206–208], the corneal stroma may be altered in microgravity and this in turn, may affect corneal tissue elasticity, corneal thickness, and its deformation during IOP measurement. Variations after corneal refractive surgery are known to limit interpretability of tonometric readings [209, 210].

A single IOP measurement cannot accurately assess IOP, as measurements vary depending on the conditions under which they are taken (e.g., supine vs. erect, resting vs. exercise, on Earth vs. microgravity) as well as the state of the patient (e.g., underlying disease state, hydration status, medications, comorbidities, and stress).

Current IOP measuring devices used in clinical settings provide measurements at a single timepoint and are not able to represent the range of spontaneous IOP variations during a 24-h cycle or daily activities in an ambulatory setting [211, 212]. This is a limitation that prevents the ability to distinguish between spontaneous IOP changes and the effects of experimental or therapeutic interventions or of extreme physiological conditions such as microgravity. Contact lens sensors [104, 213–219] and implantable intraocular IOP sensors [220, 221] that can be used by telemetry to monitor IOP continuously represent an active area of research and development.

IOP measurements should ideally be performed with the same device with adequate calibration before, during, and after spaceflight, and by the same operator. Difference between operators depending on their level of training may be associated with significant disagreement [222]. Devices that are portable, user-friendly, sensitive to monitor minor IOP changes continuously without being affected by corneal conditions are needed. The development of a reliable and sensitive IOP measuring or surrogate measuring device with [223] or without a contact lens adapted to spaceflight would offer considerable information regarding important eye changes. Grounds analog experiments should be leveraged for the development and validation of new IOP measuring technologies. The advancements are highly relevant to understanding SANS and in developing countermeasures.

Future Directions for In-Flight Studies and Ground studies

The ambitious plans for future missions to MARS will present new eye health challenges in healthy and productive astronauts and need careful consideration. Long-duration spaceflights will introduce increased ocular risks that include IOP changes.

In preparation for these missions, space agencies must accomplish the following:

1. Assess IOP-associated risk for the eye health during their active life and after retirement of astronauts.
 - 1a. Improve IOP measurements in spaceflight: The design and the development of a compact and sensitive IOP measuring device and techniques adapted to IOP changes during spaceflight should be a high priority as current devices do not respond to these requirements.
 - 1b. Design and develop a wearable device to monitor IOP and other IOP-related parameters in an ambulatory setting that allows simultaneous and continuous measurements of other physiological parameters such as blood pressure.
 - 1c. Develop novel non-invasive devices to assess specific AH dynamics components including blood flow in and around the eye underlying IOP changes to guide personalized countermeasures.
 - 1d. Leverage ground analog experiments to study and assess IOP-related risk, assess potential sex-differences, and develop and validate IOP and related parameters as biomarkers of SANS with an interdisciplinary approach.
 - 1e. Develop individualized analysis methods to assess the relationship between IOP changes over time and other eye changes dependent on systemic, CNS and ANS physiology under varying doses and duration of microgravity conditions.
2. Develop or adapt rodent and nonhuman primate models to study SANS in relation to determinants of IOP regulation: ocular blood flow, fluid homeostasis in ocular and orbital tissues, lymphatic drainage, and their modulation by autonomic nervous system and hormones. The nonhuman primate model can help to validate new miniaturized IOP measurement devices under non-invasive conditions and in a continuous manner.
3. Develop and/or adapt pharmacological and other countermeasures to prevent eye changes in SANS including IOP-related risk, and evaluate the efficacy and safety of countermeasures.
4. Evaluate the efficacy and safety of multisystem countermeasures such as exercise regimes and LBNP or their combinations to prevent IOP changes and the development of SANS.

Acknowledgments We acknowledge the support of the Canadian Space Agency [19HLSRM02] and the Henry Farrugia Research Fund. We thank Luz America Paczka-Giorgi, BSc for her support with drawings in Figs. 7.1, 7.2, 7.3, 7.4 and 7.5.

References

1. Patel ZS, Brunstetter TJ, Tarver WJ, et al. Red risks for a journey to the red planet: the highest priority human health risks for a mission to Mars. *npj Microgravity*. 2020;6(1). <https://doi.org/10.1038/s41526-020-00124-6>.
2. Lee AG, Mader TH, Gibson CR, Tarver W. Space flight-associated neuro-ocular syndrome. *JAMA Ophthalmol*. 2017;135(9):992–4. <https://doi.org/10.1001/jamaophthalmol.2017.2396>.
3. Mader TH, Gibson CR, Pass AF, et al. Optic disc edema, globe flattening, choroidal folds, and hyperopic shifts observed in astronauts after long-duration space flight. *Ophthalmology*. 2011;118(10):2058–69. <https://doi.org/10.1016/j.ophtha.2011.06.021>.

4. Patel N, Pass A, Mason S, Gibson CR, Otto C. Optical coherence tomography analysis of the optic nerve head and surrounding structures in long-duration international space station astronauts. *JAMA Ophthalmol.* 2018;136(2):193–200. <https://doi.org/10.1001/jamaophthalmol.2017.6226>.
5. Macias BR, Patel NB, Gibson CR, et al. Association of long-duration spaceflight with anterior and posterior ocular structure changes in astronauts and their recovery. *JAMA Ophthalmol.* 2020;138(5):553–9. <https://doi.org/10.1001/jamaophthalmol.2020.0673>.
6. Mader TH, Gibson CR, Pass AF, et al. Optic disc edema in an astronaut after repeat long-duration space flight. *J Neuro-ophthalmol.* 2013;33(3):249–55. <https://doi.org/10.1097/WNO.0b013e31829b41a6>.
7. Tso MO, Shih CY, McLean IW. Is there a blood-brain barrier at the optic nerve head? *Arch Ophthalmol.* 1975;93(9):815–25.
8. Hofman P, Hoyng P, van der Werf F, Vrensen GF, Schlingemann RO. Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. *Invest Ophthalmol Vis Sci.* 2001;42(5):895–901.
9. Hayreh SS. Pathogenesis of optic disc edema in raised intracranial pressure. *Prog Retin Eye Res.* 2016;50:108–44. <https://doi.org/10.1016/j.preteyeres.2015.10.001>.
10. Mathieu E, Gupta N, Ahari A, Zhou X, Hanna J, Yucel YH. Evidence for cerebrospinal fluid entry into the optic nerve via a glymphatic pathway. *Invest Ophthalmol Vis Sci.* 2017;58(11):4784–91. <https://doi.org/10.1167/iovs.17-22290>.
11. Mao XW, Nishiyama NC, Byrum SD, et al. Characterization of mouse ocular response to a 35-day spaceflight mission: evidence of blood-retinal barrier disruption and ocular adaptations. *Sci Rep.* 2019;9(1):8215. <https://doi.org/10.1038/s41598-019-44696-0>.
12. Ueki S, Suzuki Y, Igarashi H. Retinal aquaporin-4 and regulation of water inflow into the vitreous body. *Invest Ophthalmol Vis Sci.* 2021;62(2):24. <https://doi.org/10.1167/iovs.62.2.24>.
13. Fowlks WL. Meridional flow from the corona ciliaris through the pararetinal zone of the rabbit vitreous. *Invest Ophthalmol.* 1963;2:63–71.
14. Toris CB, Pederson JE. Experimental retinal detachment. VIII. Retinochoroidal horseradish peroxidase diffusion across the blood-retinal barrier. *Arch Ophthalmol.* 1985;103(2):266–9.
15. Araie M, Maurice DM. The loss of fluorescein, fluorescein glucuronide and fluorescein isothiocyanate dextran from the vitreous by the anterior and retinal pathways. *Exp Eye Res.* 1991;52(1):27–39. [https://doi.org/10.1016/0014-4835\(91\)90125-x](https://doi.org/10.1016/0014-4835(91)90125-x).
16. Convertino VA. Clinical aspects of the control of plasma volume at microgravity and during return to one gravity. *Med Sci Sports Exerc.* 1996;28(10 Suppl):S45–52. <https://doi.org/10.1097/00005768-199610000-00033>.
17. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology.* 2014. <https://doi.org/10.1016/j.ophtha.2014.05.013>
18. Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002;120(6):714–20; discussion 829–30. <https://doi.org/10.1001/archophth.120.6.714>.
19. Stepanek J, Blue RS, Parazynski S. Space medicine in the era of civilian spaceflight. *N Engl J Med.* 2019;380(11):1053–60. <https://doi.org/10.1056/NEJMra1609012>.
20. Aerospace Medical Association Task Force on Space T. Medical guidelines for space passengers. Aerospace medical association task force on space travel. *Aviat Space Environ Med.* 2001;72(10):948–50.
21. Witze A. SpaceX to launch astronauts - and a new era of private human spaceflight. *Nature.* 2020; <https://doi.org/10.1038/d41586-020-01554-8>.
22. Grant WM. Tonographic method for measuring the facility and rate of aqueous flow in human eyes. *Arch Ophthalmol* (Chicago, IL: 1929). 1950;44(2):204–14. <https://doi.org/10.1001/archophth.1950.00910020209003>.
23. Barany EH. A mathematical formulation of intraocular pressure as dependent on secretion, ultrafiltration, bulk outflow, and osmotic reabsorption of fluid. *Invest Ophthalmol.* 1963;2:584–90.
24. Kiel JW. *Ocular circulation.* Morgan & Claypool Life Science; 2010.
25. Watenpaugh DE, Hargens AR. The cardiovascular system in microgravity. Supplement 14: Handbook of physiology, environmental physiology; 1996. p. 631–74, chap 29.
26. Toris CB, Gagrani M, Ghatge D. Current methods and new approaches to assess aqueous humor dynamics *Exp Rev Ophthalmol.* 2021;1–22. <https://doi.org/10.1080/17469899.2021.1902308>
27. Macknight AD, McLaughlin CW, Peart D, Purves RD, Carre DA, Civan MM. Formation of the aqueous humor. *Clin Exp Pharmacol Physiol.* 2000;27(1-2):100–6. <https://doi.org/10.1046/j.1440-1681.2000.03208.x>.
28. Carreon T, van der Merwe E, Fellman RL, Johnstone M, Bhattacharya SK. Aqueous outflow - a continuum from trabecular meshwork to episcleral veins. *Prog Retin Eye Res.* 2017;57:108–33. <https://doi.org/10.1016/j.preteyeres.2016.12.004>.
29. Gabelt BT, Kaufman PL. Aqueous humor hydrodynamics. In: Kaufman PL, Alm A, editors. *Adler's physiology of the eye.* Mosby; 1995. p. 237–89.
30. Toris CB. Aqueous humor dynamics. In: Choplin NT, Traverso CE, editors. *Atlas of glaucoma.* 3rd ed. CRC Press; 2014. p. 13–28.
31. Johnstone M, Xin C, Tan J, Martin E, Wen J, Wang RK. Aqueous outflow regulation - 21st century concepts. *Prog Retin Eye Res.* 2020;100917. <https://doi.org/10.1016/j.preteyeres.2020.100917>
32. Alm A, Nilsson SF. Uveoscleral outflow—a review. *Exp Eye Res.* 2009;88(4):760–8. <https://doi.org/10.1016/j.exer.2008.12.012>.
33. Yucel YH, Johnston MG, Ly T, et al. Identification of lymphatics in the ciliary body of the human eye: a novel “uveolymphatic” outflow pathway. *Exp Eye Res.* 2009;89(5):810–9.
34. Yucel YH, Cardinell K, Khattak S, et al. Active lymphatic drainage from the eye measured by noninvasive photoacoustic imaging of near-infrared nanoparticles. *Invest Ophthalmol Vis Sci.* 2018;59(7):2699–707. <https://doi.org/10.1167/iovs.17-22850>.
35. Jayanetti V, Sandhu S, Lusthaus JA. The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma. *J Exp Pharmacol.* 2020;12:539–48. <https://doi.org/10.2147/JEP.S281187>. PMID: 33244278; PMCID: PMC7685378.
36. Schubert HD. Postsurgical hypotony: relationship to fistulization, inflammation, chorioretinal lesions, and the vitreous. *Surv Ophthalmol.* 1996;41(2):97–125. [https://doi.org/10.1016/s0039-6257\(96\)80001-4](https://doi.org/10.1016/s0039-6257(96)80001-4).
37. Coleman DJ. Evaluation of ciliary body detachment in hypotony. *Retina.* 1995;15(4):312–8. <https://doi.org/10.1097/00006982-199515040-00008>.
38. Schmack I, Völcker HE, Grossniklaus HE. Phthisis bulbi. *Ocular Disease.* 2010:415–23.
39. Costa VP, Arcieri ES. Hypotony maculopathy. *Acta Ophthalmol Scand.* 2007;85(6):586–97. <https://doi.org/10.1111/j.1600-0420.2007.00910.x>.
40. Williams BK Jr, Chang JS, Flynn HW Jr. Optical coherence tomography imaging of chorioretinal folds associated with hypotony maculopathy following pars plana vitrectomy. *Int Med Case Rep J.* 2015;8:199–203. <https://doi.org/10.2147/IMCRJ.S86143>.
41. Brubaker RF, Pederson JE. Ciliochoroidal detachment. *Surv Ophthalmol.* 1983;27(5):281–9. [https://doi.org/10.1016/0039-6257\(83\)90228-x](https://doi.org/10.1016/0039-6257(83)90228-x).

42. Pederson JE, Gaasterland DE, MacLellan HM. Experimental ciliochoroidal detachment. Effect on intraocular pressure and aqueous humor flow. *Arch Ophthalmol*. 1979;97(3):536–41. <https://doi.org/10.1001/archophth.1979.01020010280020>.
43. Westfall AC, Ng JD, Samples JR, Weissman JL. Hypotonus maculopathy: magnetic resonance appearance. *Am J Ophthalmol*. 2004;137(3):563–6. <https://doi.org/10.1016/j.ajo.2003.08.015>.
44. Pasquale LR, Jonas JB, Anderson D. Anatomy and physiology. In: Weinreb RN, Harris A, editors. *Ocular blood flow in glaucoma*. Kugler Publications; 2009. p. 3–13.
45. Kiel JW. Choroidal myogenic autoregulation and intraocular pressure. *Exp Eye Res*. 1994;58(5):529–43. <https://doi.org/10.1006/exer.1994.1047>.
46. Bill A, Linder M, Linder J. The protective role of ocular sympathetic vasomotor nerves in acute arterial hypertension. *Bibl Anat*. 1977;16(2):30–5.
47. McDougal DH, Gamlin PD. Autonomic control of the eye. *Comprehensive Physiol*. 2015;5(1):439–73. <https://doi.org/10.1002/cphy.c140014>.
48. Anderson DR, Grant WM. The influence of position on intraocular pressure. *Invest Ophthalmol*. 1973;12(3):204–12.
49. Jain MR, Marmion VJ. Rapid pneumatic and Mackey-Marg applanation tonometry to evaluate the postural effect on intraocular pressure. *Br J Ophthalmol*. 1976;60(10):687–93. <https://doi.org/10.1136/bjo.60.10.687>.
50. Liu JH, Kripke DF, Hoffman RE, et al. Nocturnal elevation of intraocular pressure in young adults. *Invest Ophthalmol Vis Sci*. 1998;39(13):2707–12.
51. Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. *Invest Ophthalmol Vis Sci*. 2003;44(4):1586–90.
52. Macias BR, Liu JH, Grande-Gutierrez N, Hargens AR. Intraocular and intracranial pressures during head-down tilt with lower body negative pressure. *Aerosp Med Hum Perform*. 2015;86(1):3–7. <https://doi.org/10.3357/amhp.4044.2015>.
53. Arora N, McLaren JW, Hodge DO, Sit AJ. Effect of body position on episcleral venous pressure in healthy subjects. *Invest Ophthalmol Vis Sci*. 2017;58(12):5151–6. <https://doi.org/10.1167/iov.17-22154>.
54. Carlson KH, McLaren JW, Topper JE, Brubaker RF. Effect of body position on intraocular pressure and aqueous flow. *Invest Ophthalmol Vis Sci*. 1987;28(8):1346–52.
55. Selvadurai D, Hodge D, Sit AJ. Aqueous humor outflow facility by tonography does not change with body position. *Invest Ophthalmol Vis Sci*. 2010;51(3):1453–7. <https://doi.org/10.1167/iov.09-4058>.
56. Kiel JW, van Heuven WA. Ocular perfusion pressure and choroidal blood flow in the rabbit. *Invest Ophthalmol Vis Sci*. 1995;36(3):579–85.
57. Dumskyj MJ, Mathias CJ, Dore CJ, Bleasdale-Barr K, Kohner EM. Postural variation in intraocular pressure in primary chronic autonomic failure. *J Neurol*. 2002;249(6):712–8. <https://doi.org/10.1007/s00415-002-0697-1>.
58. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. *Arch Ophthalmol*. 1981;99(4):635–49.
59. Morgan WH, Yu DY, Alder VA, et al. The correlation between cerebrospinal fluid pressure and retrolaminar tissue pressure. *Invest Ophthalmol Vis Sci*. 1998;39(8):1419–28.
60. Liu KC, Fleischman D, Lee AG, Killer HE, Chen JJ, Bhatti MT. Current concepts of cerebrospinal fluid dynamics and the translaminar cribrosa pressure gradient: a paradigm of optic disk disease. *Surv Ophthalmol*. 2020;65(1):48–66. <https://doi.org/10.1016/j.survophthal.2019.08.005>.
61. Ren R, Jonas JB, Tian G, et al. Cerebrospinal fluid pressure in glaucoma: a prospective study. *Ophthalmology*. 2010;117(2):259–66. <https://doi.org/10.1016/j.ophtha.2009.06.058>.
62. Eklund A, Johannesson G, Johansson E, et al. The pressure difference between eye and brain changes with posture. *Ann Neurol*. 2016;80(2):269–76. <https://doi.org/10.1002/ana.24713>.
63. Jonas JB, Xu L. Histological changes of high axial myopia. *Eye (Lond)*. 2014;28(2):113–7. <https://doi.org/10.1038/eye.2013.223>.
64. Jasien JV, Samuels BC, Johnston JM, Downs JC. Effect of body position on intraocular pressure (IOP), intracranial pressure (ICP), and translaminar pressure (TLP) via continuous wireless telemetry in nonhuman primates (NHPs). *Invest Ophthalmol Vis Sci*. 2020;61(12):18. <https://doi.org/10.1167/iov.61.12.18>.
65. Jasien JV, Samuels BC, Johnston JM, Downs JC. Diurnal cycle of translaminar pressure in nonhuman primates quantified with continuous wireless telemetry. *Invest Ophthalmol Vis Sci*. 2020;61(2):37. <https://doi.org/10.1167/iov.61.2.37>.
66. Bradac GB. Common (CCA) and internal (ICA) carotid artery. In: Bradac GB, editor. *Applied cerebral angiography*, vol. 163. Springer; 2017. p. 11–34.
67. Bradac GB. Cerebral veins. In: Bradac GB, editor. *Applied cerebral angiography*, vol. 163. Springer; 2017. p. 129–62.
68. Bradac GB. Extracranial venous drainage. In: Bradac GB, editor. *Appl Cerebral Angiogr*, vol. 163. Springer; 2017. p. 163–5.
69. Nassr MA, Morris CL, Netland PA, Karcioğlu ZA. Intraocular pressure change in orbital disease. *Surv Ophthalmol*. 2009;54(5):519–44. <https://doi.org/10.1016/j.survophthal.2009.02.023>.
70. Greslechner R, Oberacher-Velten I. Glaucoma due to elevated episcleral venous pressure. *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft*. 2019;116(5):423–9. <https://doi.org/10.1007/s00347-018-0828-4>.
71. Phelps CD. The pathogenesis of glaucoma in Sturge-Weber syndrome. *Ophthalmology*. 1978;85(3):276–86. [https://doi.org/10.1016/s0161-6420\(78\)35667-0](https://doi.org/10.1016/s0161-6420(78)35667-0).
72. Shiao T, Armogan N, Yan DB, Thomson HG, Levin AV. The role of episcleral venous pressure in glaucoma associated with Sturge-Weber syndrome. *J AAPOS*. 2012;16(1):61–4. <https://doi.org/10.1016/j.jaaapos.2011.09.014>.
73. Silverstein M, Salvin J. Ocular manifestations of Sturge-Weber syndrome. *Curr Opin Ophthalmol*. 2019;30(5):301–5. <https://doi.org/10.1097/ICU.0000000000000597>.
74. Arora KS, Quigley HA, Comi AM, Miller RB, Jampel HD. Increased choroidal thickness in patients with Sturge-Weber syndrome. *JAMA Ophthalmol*. 2013;131(9):1216–9. <https://doi.org/10.1001/jamaophthalmol.2013.4044>.
75. Del Noce C, Vagge A, Nicolo M, Traverso CE. Evaluation of choroidal thickness and choroidal vascular blood flow in patients with thyroid-associated orbitopathy (TAO) using SD-OCT and angio-OCT. *Graefes Arch Clin Exp Ophthalmol*. 2020;258(5):1103–7. <https://doi.org/10.1007/s00417-020-04616-9>.
76. Lai FHP, Iao TWU, Ng DSC, et al. Choroidal thickness in thyroid-associated orbitopathy. *Clin Exp Ophthalmol*. 2019;47(7):918–24. <https://doi.org/10.1111/ceo.13525>.
77. Stern C, Yucel YH, zu Eulenburg P, Pavy-Le Traon A, Grove Petersen L. Eye-Brain Axis in Microgravity: Implications for Spaceflight-Associated Neuro-ocular Syndrome. *npj Microgravity*. (In press).
78. Dickinson AJ, Gausas RE. Orbital lymphatics: do they exist? *Eye (Lond)*. 2006;20(10):1145–8. <https://doi.org/10.1038/sj.eye.6702378>.
79. Killer HE, Laeng HR, Groscurth P. Lymphatic capillaries in the meninges of the human optic nerve. *J Neuro-ophthalmol*. 1999;19(4):222–8.
80. Malliani A. Principles of cardiovascular neural regulation in health and disease. Kluwer Academic Publishers; 2000.
81. Gibbons CH. Basics of autonomic nervous system function. *Handbook of clinical neurology*. 2019;160:407–18. <https://doi.org/10.1016/b978-0-444-64032-1.00027-8>.

82. Goldstein DS. Differential responses of components of the autonomic nervous system. *Handb Clin Neurol*. 2013;117:13–22. <https://doi.org/10.1016/b978-0-444-53491-0.00002-x>.
83. Tobaldini E, Colombo G, Porta A, Montano N. The autonomic nervous system. In: Choukér A, editor. *Stress challenges and immunity in space*. Springer Nature; 2020. p. 123–43.
84. Selbach JM, Rohen JW, Steuhl KP, Lutjen-Drecoll E. Angio-architecture and innervation of the primate anterior episclera. *Curr Eye Res*. 2005;30(5):337–44. <https://doi.org/10.1080/02713680590934076>.
85. Selbach JM, Gottanka J, Wittmann M, Lutjen-Drecoll E. Efferent and afferent innervation of primate trabecular meshwork and scleral spur. *Invest Ophthalmol Vis Sci*. 2000;41(8):2184–91.
86. Strohmaier CA, Reitsamer HA, Kiel JW. Episcleral venous pressure and IOP responses to central electrical stimulation in the rat. *Invest Ophthalmol Vis Sci*. 2013;54(10):6860–6. <https://doi.org/10.1167/iovs.13-12781>.
87. Steinle JJ, Krizsan-Agbas D, Smith PG. Regional regulation of choroidal blood flow by autonomic innervation in the rat. *Am J Physiol Regul Integr Comp Physiol*. 2000;279(1):R202–9. <https://doi.org/10.1152/ajpregu.2000.279.1.R202>.
88. Parver LM. Temperature modulating action of choroidal blood flow. *Eye (Lond)*. 1991;5(Pt 2):181–5. <https://doi.org/10.1038/eye.1991.32>.
89. Parver LM, Auker C, Carpenter DO. Choroidal blood flow as a heat dissipating mechanism in the macula. *Am J Ophthalmol*. 1980;89(5):641–6. [https://doi.org/10.1016/0002-9394\(80\)90280-9](https://doi.org/10.1016/0002-9394(80)90280-9).
90. Stahn AC, Werner A, Opatz O, et al. Increased core body temperature in astronauts during long-duration space missions. *Sci Rep*. 2017;7(1):16180. <https://doi.org/10.1038/s41598-017-15560-w>.
91. Alexander DW, Berson FG, Epstein DL. A clinical trial of timolol and epinephrine in the treatment of primary open-angle glaucoma. *Ophthalmology*. 1988;95(2):247–51. [https://doi.org/10.1016/s0161-6420\(88\)33205-7](https://doi.org/10.1016/s0161-6420(88)33205-7).
92. Jay WM, Aziz MZ, Green K. Effect of topical epinephrine and timolol on ocular and optic nerve blood flow in phakic and aphakic rabbit eyes. *Curr Eye Res*. 1984;3(10):1199–202. <https://doi.org/10.3109/02713688409000822>.
93. Wang YL, Hayashi M, Yablonski ME, Toris CB. Effects of multiple dosing of epinephrine on aqueous humor dynamics in human eyes. *J Ocul Pharmacol Ther*. 2002;18(1):53–63. <https://doi.org/10.1089/108076802317233216>.
94. Ye M, Chen Z, Li M, Chen W, Zhang H, Wang J. Effect of topical application of adrenaline on Schlemm canal, trabecular meshwork and intraocular pressure. *Medicine (Baltimore)*. 2019;98(22):e15558. <https://doi.org/10.1097/md.00000000000015558>.
95. Bachmann SB, Gsponer D, Montoya-Zegarra JA, et al. A distinct role of the autonomic nervous system in modulating the function of lymphatic vessels under physiological and tumor-draining conditions. *Cell Rep*. 2019;27(11):3305–3314 e13. <https://doi.org/10.1016/j.celrep.2019.05.050>.
96. Lehman RA, Krupin T, Podos SM. Experimental effect of intracranial hypertension upon intraocular pressure. *J Neurosurg*. 1972;36(1):60–6. <https://doi.org/10.3171/jns.1972.36.1.0060>.
97. Ficarrotta KR, Passaglia CL. Intracranial pressure modulates aqueous humour dynamics of the eye. *J Physiol*. 2020;598(2):403–13. <https://doi.org/10.1113/JP278768>.
98. Denis P, Nordmann JP, Elena PP, Saraux H, Lapalus P. Central nervous system control of intraocular pressure. *Fundam Clin Pharmacol*. 1994;8(3):230–7. <https://doi.org/10.1111/j.1472-8206.1994.tb00803.x>.
99. Trzeciakowski JP. Central control of intraocular pressure. *J Ocular Pharmacol*. 1987;3(4):367–78. <https://doi.org/10.1089/jop.1987.3.367>.
100. Samuels BC, Hammes NM, Johnson PL, Shekhar A, McKinnon SJ, Allingham RR. Dorsomedial/Perifornical hypothalamic stimulation increases intraocular pressure, intracranial pressure, and the translaminal pressure gradient. *Invest Ophthalmol Vis Sci*. 2012;53(11):7328–35. <https://doi.org/10.1167/iovs.12-10632>.
101. Krupin T, Podos SM, Becker B. Alteration of intraocular pressure after third ventricle injections of osmotic agents. *Am J Ophthalmol*. 1973;76(6):948–52. [https://doi.org/10.1016/0002-9394\(73\)90087-1](https://doi.org/10.1016/0002-9394(73)90087-1).
102. Krupin T, Koloms BA, Klutho L, Webb G, Becker B. Increased intraocular pressure and hyperthermia following administration of substance P into rabbit third ventricle. *Exp Eye Res*. 1982;34(3):319–24.
103. Krupin T, Webb GW, Barbosa AT, Gulli B, Levine J, Becker B. Central effects of thyrotropin-releasing hormone and arginine vasopressin on intraocular pressure in rabbits. *Invest Ophthalmol Vis Sci*. 1984;25(8):932–7.
104. Aptel F, Weinreb RN, Chiquet C, Mansouri K. 24-h monitoring devices and nyctohemeral rhythms of intraocular pressure. *Prog Retin Eye Res*. 2016;55:108–48. <https://doi.org/10.1016/j.pretyeres.2016.07.002>.
105. Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of intraocular pressure in young adults with moderate to severe myopia. *Invest Ophthalmol Vis Sci*. 2002;43(7):2351–5.
106. Liu JH. Circadian rhythm of intraocular pressure. *J Glaucoma*. 1998;7(2):141–7.
107. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. *Am J Ophthalmol*. 2005;139(2):320–4. <https://doi.org/10.1016/j.ajo.2004.09.062>.
108. Liu JH, Sit AJ, Weinreb RN. Variation of 24-hour intraocular pressure in healthy individuals: right eye versus left eye. *Ophthalmology*. 2005;112(10):1670–5. <https://doi.org/10.1016/j.ophtha.2005.05.007>.
109. Sit AJ, Nau CB, McLaren JW, Johnson DH, Hodge D. Circadian variation of aqueous dynamics in young healthy adults. *Invest Ophthalmol Vis Sci*. 2008;49(4):1473–9. <https://doi.org/10.1167/iovs.07-1139>.
110. Nau CB, Malihi M, McLaren JW, Hodge DO, Sit AJ. Circadian variation of aqueous humor dynamics in older healthy adults. *Invest Ophthalmol Vis Sci*. 2013;54(12):7623–9. <https://doi.org/10.1167/iovs.12-12690>.
111. Doshi AB, Liu JHK, Weinreb RN. Circadian Changes in intraocular pressure. In: Grehn F, Stamper R, editor. *Glaucoma*. Springer; 2009:chap 3.
112. Tsuchiya S, Buhr ED, Higashide T, Sugiyama K, Van Gelder RN. Light entrainment of the murine intraocular pressure circadian rhythm utilizes non-local mechanisms. *PLoS One*. 2017;12(9):e0184790. <https://doi.org/10.1371/journal.pone.0184790>.
113. Tsuchiya S, Sugiyama K, Van Gelder RN. Adrenal and glucocorticoid effects on the circadian rhythm of murine intraocular pressure. *Invest Ophthalmol Vis Sci*. 2018;59(13):5641–7. <https://doi.org/10.1167/iovs.18-24785>.
114. Ikegami K, Shige-yoshi Y, Masubuchi S. Circadian regulation of IOP rhythm by dual pathways of glucocorticoids and the sympathetic nervous system. *Invest Ophthalmol Vis Sci*. 2020;61(3):26. <https://doi.org/10.1167/iovs.61.3.26>
115. Gundel A, Polyakov VV, Zully J. The alteration of human sleep and circadian rhythms during spaceflight. *J Sleep Res*. 1997;6(1):1–8. <https://doi.org/10.1046/j.1365-2869.1997.00028.x>.
116. Dijk DJ, Neri DF, Wyatt JK, et al. Sleep, performance, circadian rhythms, and light-dark cycles during two space shuttle flights. *Am J Physiol Regulat Integr Comp Physiol*. 2001;281(5):R1647–64. <https://doi.org/10.1152/ajpregu.2001.281.5.R1647>.

117. Draeger J, Schwartz R, Groenhoff S, Stern C. Self-tonometry under microgravity conditions. *Aviat Space Environ Med.* 1995;66(6):568–70.
118. Schwartz R, Draeger J, Groenhoff S, Flade KD. Results of self-tonometry during the 1st German-Russian MIR mission 1992. *Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.* 1993;90(6):640–2. Ergebnisse der Selbsttonometrie während der 1. Deutsch-Russischen MIR-Mission 1992.
119. Draeger J, Schwartz R, Groenhoff S, Stern C. Self tonometry during the German 1993 Spacelab D2 mission. *Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.* 1994;91(5):697–9. Selbsttonometrie während der Deutschen Spacelab-D2-Mission 1993.
120. Liu H, Fan S, Gulati V, et al. Aqueous humor dynamics during the day and night in healthy mature volunteers. *Arch Ophthalmol.* Mar 2011;129(3):269–75. <https://doi.org/10.1001/archophthalmol.2011.4>.
121. Stenger MB, Tarver WJ, Brunstetter T. NASA Human Research Program Evidence Report: Risk of Spaceflight Associated Neuro-Ocular Syndrome (SANS). NASA. <https://humanresearchroadmap.nasa.gov/evidence/reports/SANS.pdf?rnd=0.434276635495143>. Accessed 15 Feb 2018
122. Chung KY, Woo SJ, Yi S, et al. Diurnal pattern of intraocular pressure is affected by microgravity when measured in space with the pressure phosphene tonometer (PPT). *J Glaucoma.* 2011;20(8):488–91. <https://doi.org/10.1097/IJG.0b013e3181f464d2>.
123. Mader TH, Taylor GR, Hunter N, Caputo M, Meehan RT. Intraocular pressure, retinal vascular, and visual acuity changes during 48 hours of 10 degrees head-down tilt. *Aviat Space Environ Med.* 1990;61(9):810–3.
124. Norsk P. Adaptation of the cardiovascular system to weightlessness: surprises, paradoxes and implications for deep space missions. *Acta Physiol.* 2020;228(3):e13434. <https://doi.org/10.1111/apha.13434>.
125. The Visual Impairment Intracranial Pressure Summit Report; 2011.
126. Macias BR, Liu JHK, Otto C, Hargens A. *Intracranial Pressure and its Effect on Vision on Space and on Earth.* World Scientific Publishing Co; 2017.
127. Lawley JS, Petersen LG, Howden EJ, et al. Effect of gravity and microgravity on intracranial pressure. *J Physiol.* 2017;595(6):2115–27. <https://doi.org/10.1113/jp273557>.
128. Draeger J, Schwartz R, Groenhoff S, Stern C. Self-tonometry under microgravity conditions. *Clin Investig.* 1993;71(9):700–3. <https://doi.org/10.1007/BF00209723>.
129. Law J, Van Baalen M, Foy M, et al. Relationship between carbon dioxide levels and reported headaches on the international space station. *J Occup Environ Med.* 2014;56(5):477–83. <https://doi.org/10.1097/JOM.0000000000000158>.
130. Samuel JR, Beaugie A. Effect of carbon dioxide on the intraocular pressure in man during general anaesthesia. *Br J Ophthalmol.* 1974;58(1):62–7. <https://doi.org/10.1136/bjo.58.1.62>.
131. Kielar RA, Teraslinna P, Kearney JT, Barker D. Effect of changes in Pco₂ on intraocular tension. *Invest Ophthalmol Vis Sci.* 1977;16(6):534–7.
132. Petounis AD, Chondreli S, Vadaluka-Sekioti A. Effect of hypercapnea and hyperventilation on human intraocular pressure general anaesthesia following acetazolamide administration. *Br J Ophthalmol.* 1980;64(6):422–5. <https://doi.org/10.1136/bjo.64.6.422>.
133. Avunduk AM, Yilmaz B, Sahin N, Kapicioglu Z, Dayanir V. The comparison of intraocular pressure reductions after isometric and isokinetic exercises in normal individuals. *Ophthalmologica.* 1999;213(5):290–4. <https://doi.org/10.1159/000027441>.
134. Harris A, Malinovsky V, Martin B. Correlates of acute exercise-induced ocular hypotension. *Invest Ophthalmol Vis Sci.* 1994;35(11):3852–7.
135. Kiuchi Y, Mishima HK, Hotehama Y, Furumoto A, Hirota A, Onari K. Exercise intensity determines the magnitude of IOP decrease after running. *Jpn J Ophthalmol.* 1994;38(2):191–5.
136. Kielar RA, Teraslinna P, Rowe DG, Jackson J. Standardized aerobic and anaerobic exercise: differential effects on intraocular tension, blood pH, and lactate. *Invest Ophthalmol.* 1975;14(10):782–5.
137. Ashkenazi I, Melamed S, Blumenthal M. The effect of continuous strenuous exercise on intraocular pressure. *Invest Ophthalmol Vis Sci.* 1992;33(10):2874–7.
138. Blanco S, Peralta S, Morales ME, et al. Hyaluronate nanoparticles as a delivery system to carry neuroglobin to the brain after stroke. *Pharmaceutics.* 2020;12(1). <https://doi.org/10.3390/pharmaceutics12010040>
139. Podos SM, Krupin T, Becker B. Effect of small-dose hyperosmotic injections on intraocular pressure of small animals and man when optic nerves are transected and intact. *Am J Ophthalmol.* 1971;71(4):898–903. [https://doi.org/10.1016/0002-9394\(71\)90264-9](https://doi.org/10.1016/0002-9394(71)90264-9).
140. Passo MS, Goldberg L, Elliot DL, Van Buskirk EM. Exercise conditioning and intraocular pressure. *Am J Ophthalmol.* 1987;103(6):754–7. [https://doi.org/10.1016/s0002-9394\(14\)74388-0](https://doi.org/10.1016/s0002-9394(14)74388-0).
141. Qureshi IA. Effects of exercise on intraocular pressure in physically fit subjects. *Clin Exp Pharmacol Physiol.* 1996;23(8):648–52. <https://doi.org/10.1111/j.1440-1681.1996.tb01751.x>.
142. Dane S, Kocer I, Demirel H, Ucoq K, Tan U. Effect of acute submaximal exercise on intraocular pressure in athletes and sedentary subjects. *Int J Neurosci.* 2006;116(10):1223–30. <https://doi.org/10.1080/00207450500522501>.
143. Dickerman RD, Smith GH, Langham-Roof L, McConathy WJ, East JW, Smith AB. Intra-ocular pressure changes during maximal isometric contraction: does this reflect intra-cranial pressure or retinal venous pressure? *Neuro Res.* 1999;21(3):243–6. <https://doi.org/10.1080/01616412.1999.11740925>.
144. Brody S, Erb C, Veit R, Rau H. Intraocular pressure changes: the influence of psychological stress and the Valsalva maneuver. *Biol Psychol.* 1999;51(1):43–57. [https://doi.org/10.1016/s0301-0511\(99\)00012-5](https://doi.org/10.1016/s0301-0511(99)00012-5).
145. Swanson S. Human Physiology and Countermeasures for Spaceflight from the Perspective of an ISS Astronaut. 2019 IEEE Aerospace Conference, 2019:1–6.
146. Pandiarajan M, Hargens AR. Ground-Based Analogs for Human Spaceflight. *Frontiers in physiology.* 2020;11:716. doi:10.3389/fphys.2020.00716147. Kermorgant M, Nasr N, Czosnyka M, et al. Impacts of Microgravity Analogs to Spaceflight on Cerebral Autoregulation. *Frontiers in physiology.* 2020;11:778. <https://doi.org/10.3389/fphys.2020.00778>.
147. Genin AM, Sorokin PA. Prolonged restriction of mobility as a model of the effects of weightlessness on the human body. *Problems of space biology.* Science Publishers; 1969.
148. Taibbi G, Cromwell RL, Zanello SB, et al. Ocular outcomes comparison between 14- and 70-day head-down-tilt bed rest. *Invest Ophthalmol Vis Sci.* 2016;57(2):495–501. <https://doi.org/10.1167/iovs.15-18530>.
149. Taibbi G, Cromwell RL, Zanello SB, et al. Ocular outcomes evaluation in a 14-day head-down bed rest study. *Aviat Space Environ Med.* 2014;85(10):983–92. <https://doi.org/10.3357/ASEM.4055.2014>.
150. Laurie SS, Lee SMC, Macias BR, et al. Optic disc edema and chorioidal engorgement in astronauts during spaceflight and individuals exposed to bed rest. *JAMA Ophthalmol.* 2020;138(2):165–72. <https://doi.org/10.1001/jamaophthalmol.2019.5261>.

151. Chiquet C, Custaud MA, Le Traon AP, Millet C, Gharib C, Denis P. Changes in intraocular pressure during prolonged (7-day) head-down tilt bedrest. *J Glaucoma*. 2003;12(3):204–8. <https://doi.org/10.1097/00061198-200306000-00004>.
152. Christensen NJ, Heer M, Ivanova K, Norsk P. Sympathetic nervous activity decreases during head-down bed rest but not during microgravity. *J Appl Physiol*. 2005;99(4):1552–7. <https://doi.org/10.1152/jappphysiol.00017.2005>.
153. Xu X, Li L, Cao R, et al. Intraocular pressure and ocular perfusion pressure in myopes during 21 min head-down rest. *Aviat Space Environ Med*. 2010;81(4):418–22.
154. Caprihan A, Sanders JA, Cheng HA, Loeppky JA. Effect of head-down tilt on brain water distribution. *European J Appl Physiol Occup Physiol*. 1999;79(4):367–73. <https://doi.org/10.1007/s004210050522>.
155. Navasiolava NM, Custaud MA, Tomilovskaya ES, et al. Long-term dry immersion: review and prospects. *Eur J Appl Physiol*. 2011;111(7):1235–60. <https://doi.org/10.1007/s00421-010-1750-x>.
156. Tomilovskaya E, Shigueva T, Sayenko D, Rukavishnikov I, Kozlovskaya I. Dry immersion as a ground-based model of microgravity physiological effects. *Front Physiol*. 2019;10:284. <https://doi.org/10.3389/fphys.2019.00284>.
157. Iwase S, Sugiyama Y, Miwa C, et al. Effects of three days of dry immersion on muscle sympathetic nerve activity and arterial blood pressure in humans. *J Auton Nerv Syst*. 2000;79(2–3):156–64. [https://doi.org/10.1016/s0165-1838\(99\)00076-4](https://doi.org/10.1016/s0165-1838(99)00076-4)
158. Kermorgant M, Leca F, Nasr N, et al. Impacts of simulated weightlessness by dry immersion on optic nerve sheath diameter and cerebral autoregulation. *Front Physiol*. 2017;8:780. <https://doi.org/10.3389/fphys.2017.00780>.
159. Man'ko OM, Smoleevskii AE, Tomilovskaya ES, Kozlovskaya IB. Effect of five-day “dry” immersion on eye hydrodynamics. *Hum Physiol*. 2021;46(7):792–7. <https://doi.org/10.1134/s0362119720070105>.
160. Hackney KJ, Scott JM, Hanson AM, English KL, Downs ME, Ploutz-Snyder LL. The astronaut-athlete: optimizing human performance in space. *J Strength Cond Res*. 2015;29(12):3531–45. <https://doi.org/10.1519/JSC.0000000000001191>.
161. Risner D, Ehrlich R, Kheradiya NS, Siesky B, McCranor L, Harris A. Effects of exercise on intraocular pressure and ocular blood flow: a review. *J Glaucoma*. 2009;18(6):429–36. <https://doi.org/10.1097/IJG.0b013e31818fa5f3>.
162. Martin B, Harris A, Hammel T, Malinovsky V. Mechanism of exercise-induced ocular hypotension. *Invest Ophthalmol Vis Sci*. 1999;40(5):1011–5.
163. Okuno T, Sugiyama T, Kohyama M, Kojima S, Oku H, Ikeda T. Ocular blood flow changes after dynamic exercise in humans. *Eye (Lond)*. 2006;20(7):796–800. <https://doi.org/10.1038/sj.eye.6702004>.
164. Taibbi G, Cromwell RL, Zanello SB, et al. Ophthalmological evaluation of integrated resistance and aerobic training during 70-day bed rest. *Aerosp Med Hum Perform*. 2017;88(7):633–40. <https://doi.org/10.3357/AMHP.4768.2017>.
165. Scott JM, Tucker WJ, Martin D, et al. Association of exercise and swimming goggles with modulation of cerebro-ocular hemodynamics and pressures in a model of spaceflight-associated neuro-ocular syndrome. *JAMA Ophthalmol*. 2019. <https://doi.org/10.1001/jamaophthalmol.2019.0459>
166. Passo MS, Goldberg L, Elliot DL, Van Buskirk EM. Exercise training reduces intraocular pressure among subjects suspected of having glaucoma. *Arch Ophthalmol*. 1991;109(8):1096–8. <https://doi.org/10.1001/archophth.1991.01080080056027>.
167. Kozlovskaya IB, Grigoriev AI, Stepantsov VI. Countermeasure of the negative effects of weightlessness on physical systems in long-term space flights. *Acta Astronaut*. 1995;36(8–12):661–8.
168. Lawley JS, Babu G, Janssen S, et al. Daily generation of a footward fluid shift attenuates ocular changes associated with head-down tilt bedrest. *J Appl Physiol*. 2020. <https://doi.org/10.1152/jappphysiol.00250.2020>
169. Johnson BD, van Helmond N, Curry TB, van Buskirk CM, Convertino VA, Joyner MJ. Reductions in central venous pressure by lower body negative pressure or blood loss elicit similar hemodynamic responses. *J Appl Physiol*. 2014;117(2):131–41. <https://doi.org/10.1152/jappphysiol.00070.2014>
170. Petersen LG, Hargens A, Bird EM, Ashari N, Saalfeld J, Petersen JCG. Mobile lower body negative pressure suit as an integrative countermeasure for spaceflight. *Aerosp Med Hum Perform*. 2019;90(12):993–9. <https://doi.org/10.3357/AMHP.5408.2019>.
171. Clement GR, Buckley AP, Paloski WH. Artificial gravity as a countermeasure for mitigating physiological deconditioning during long-duration space missions. *Front Syst Neurosci*. 2015;9:92. <https://doi.org/10.3389/fnsys.2015.00092>.
172. Hargens AR, Bhattacharya R, Schneider SM. Space physiology VI: exercise, artificial gravity, and countermeasure development for prolonged space flight. *Eur J Appl Physiol*. 2013;113(9):2183–92. <https://doi.org/10.1007/s00421-012-2523-5>.
173. Evans JM, Knapp CF, Goswami N. Artificial gravity as a countermeasure to the cardiovascular deconditioning of spaceflight: gender perspectives. *Front Physiol*. 2018;9:716. <https://doi.org/10.3389/fphys.2018.00716>.
174. Clement G, Pavy-Le TA. Centrifugation as a countermeasure during actual and simulated microgravity: a review. *Eur J Appl Physiol*. 2004;92(3):235–48. <https://doi.org/10.1007/s00421-004-1118-1>.
175. Anderson AP, Butterfield JS, Subramanian PS, Clark TK. Intraocular pressure and cardiovascular alterations investigated in artificial gravity as a countermeasure to spaceflight associated neuro-ocular syndrome. *J Appl Physiol*. 2018;125(2):567–76. <https://doi.org/10.1152/jappphysiol.00082.2018>.
176. Shimbo M, Kudo T, Hamada M, et al. Ground-based assessment of JAXA mouse habitat cage unit by mouse phenotypic studies. *Exp Anim*. 2016;65(2):175–87. <https://doi.org/10.1538/expanim.15-0077>.
177. Hoban-Higgins TM, Robinson EL, Fuller CA. Primates in space flight. *Advances in space biology and medicine*. Elsevier. 2005:303–25.
178. Bill A. Aqueous humor dynamics in monkeys (*Macaca irus* and *Cercopithecus ethiops*). *Exp Eye Res*. 1971;11(2):195–206.
179. Picaut S, Dalkara D, Marazova K, Goureau O, Roska B, Sahel JA. The primate model for understanding and restoring vision. *Proc Natl Acad Sci USA*. 2019. <https://doi.org/10.1073/pnas.1902292116>
180. Rasmussen CA, Kaufman PL. Primate glaucoma models. *J Glaucoma*. 2005;14(4):311–4. <https://doi.org/10.1097/OI.ijg.0000169409.01635.bc>.
181. Burgoyne CF. The non-human primate experimental glaucoma model. *Exp Eye Res*. 2015;141:57–73. <https://doi.org/10.1016/j.exer.2015.06.005>.
182. Cornish KG, Hughes K, Dreessen A, Olguin M. Head-out immersion in the non-human primate: a model of cardiovascular deconditioning during microgravity. *Aviat Space Environ Med*. 1999;70(8):773–9.
183. Globus RK, Morey-Holton E. Hindlimb unloading: rodent analog for microgravity. *J Appl Physiol*. 2016;120(10):1196–206. <https://doi.org/10.1152/jappphysiol.00997.2015>.
184. Morey-Holton E, Globus RK, Kaplansky A, Durnova G. The hindlimb unloading rat model: literature overview, technique update and comparison with space flight data. *Advances in space biology and medicine*. Elsevier; 2005:7–40.
185. Gashev AA, Delp MD, Zawieja DC. Inhibition of active lymph pump by simulated microgravity in rats. *Am J Physiol Heart Circ*

- Physiol. 2006;290(6):H2295–308. <https://doi.org/10.1152/ajp-heart.00260.2005>.
186. Shellock FG, Swan HJ, Rubin SA. Early central venous pressure changes in the rat during two different levels of head-down suspension. *Aviat Space Environ Med.* 1985;56(8):791–5.
 187. Millar JC, Clark AF, Pang IH. Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion. *Invest Ophthalmol Vis Sci.* 2011;52(2):685–94. <https://doi.org/10.1167/iovs.10-6069>.
 188. Perlman RL. Mouse models of human disease: an evolutionary perspective. *Evol Med Public Health.* 2016;2016(1):170–6. <https://doi.org/10.1093/emph/eow014>.
 189. Tam AL, Gupta N, Zhang Z, Yucel YH. Quantum dots trace lymphatic drainage from the mouse eye. *Nanotechnology.* 2011;22(42):425101. <https://doi.org/10.1088/0957-4484/22/42/425101>.
 190. Koh L, Zakharov A, Johnston M. Integration of the subarachnoid space and lymphatics: is it time to embrace a new concept of cerebrospinal fluid absorption? *Cerebrospinal Fluid Res.* 2005;2:6.
 191. Mathieu E, Gupta N, Macdonald RL, Ai J, Yucel YH. In vivo imaging of lymphatic drainage of cerebrospinal fluid in mouse. *Fluids Barriers CNS.* 2013;10(1):35. <https://doi.org/10.1186/2045-8118-10-35>.
 192. Yucel YH, Cheng F, Cardinell K, Zhou X, Irving H, Gupta N. Age-related decline of lymphatic drainage from the eye: a non-invasive in vivo photoacoustic tomography study. *Exp Eye Res.* 2020;108029. <https://doi.org/10.1016/j.exer.2020.108029>.
 193. Hanna J, Yucel YH, Zhou X, Kim N, Irving H, Gupta N. Beta-adrenergic glaucoma drugs reduce lymphatic clearance from the eye: A sequential photoacoustic imaging study. *Exp Eye Res.* Sep 29 2021;212:108775. <https://doi.org/10.1016/j.exer.2021.108775>
 194. Fogagnolo P, Rossetti L, Mazzolani F, Orzalesi N. Circadian variations in central corneal thickness and intraocular pressure in patients with glaucoma. *Br J Ophthalmol.* 2006;90(1):24–8. <https://doi.org/10.1136/bjo.2005.079285>.
 195. Barkana Y. Postural change in intraocular pressure: a comparison of measurement with a Goldmann tonometer, Tonopen XL, pneumatonometer, and HA-2. *J Glaucoma.* 2014;23(1):e23–8. <https://doi.org/10.1097/IJG.0b013e3182a0762f>.
 196. Barkana Y, Gutfreund S. Measurement of the difference in intraocular pressure between the sitting and lying body positions in healthy subjects: direct comparison of the Icare Pro with the Goldmann applanation tonometer, Pneumatonometer and Tonopen XL. *Clin Exp Ophthalmol.* 2014;42(7):608–14. <https://doi.org/10.1111/ceo.12272>.
 197. Moster SJ, Fakhraie G, Venketesh R, Moster ML, Zhao Y, Moster MR. Relationship of central corneal thickness to postural IOP changes in patients with and without glaucoma in southern India. *Int Ophthalmol.* 2012;32(4):307–11. <https://doi.org/10.1007/s10792-012-9522-8>.
 198. Cheng J, Salam T, Russell PJ, Heath DG, Kotecha A. Dynamic contour tonometer and Goldmann applanation tonometer performance in a developing world setting: intraocular pressure measurement acquisition and precision. *J Glaucoma.* 2013;22(9):736–9. <https://doi.org/10.1097/IJG.0b013e31825c0f9e>.
 199. Salim S, Du H, Wan J. Comparison of intraocular pressure measurements and assessment of intraobserver and interobserver reproducibility with the portable ICare rebound tonometer and Goldmann applanation tonometer in glaucoma patients. *J Glaucoma.* 2013;22(4):325–9. <https://doi.org/10.1097/IJG.0b013e318237caa2>.
 200. Fogagnolo P, Figus M, Frezzotti P, et al. Test-retest variability of intraocular pressure and ocular pulse amplitude for dynamic contour tonometry: a multicentre study. *Br J Ophthalmol.* 2010;94(4):419–23. <https://doi.org/10.1136/bjo.2009.165142>.
 201. Gurov AS. The TON-1 compact eye tonometer-tonograph. *Biomed Eng.* 1995;29(3):163–5. <https://doi.org/10.1007/BF00560501>.
 202. Brandt JD. Stop “Adjusting” intraocular pressure measurements. *JAMA Ophthalmol.* 2017;135(6):608–9. <https://doi.org/10.1001/jamaophthalmol.2017.1035>.
 203. Bao F, Huang Z, Huang J, et al. Clinical evaluation of methods to correct intraocular pressure measurements by the goldmann applanation tonometer, ocular response analyzer, and corvis ST tonometer for the effects of corneal stiffness parameters. *J Glaucoma.* 2016;25(6):510–9. <https://doi.org/10.1097/IJG.0000000000000359>.
 204. Willekens K, Rocha R, Van Keer K, et al. Review on dynamic contour tonometry and ocular pulse amplitude. *Ophthalmic Res.* 2015;55(2):91–8. <https://doi.org/10.1159/000441796>.
 205. Lanza M, Rinaldi M, Carnevale UAG, di Staso S, Sconocchia MB, Costagliola C. Analysis of differences in intraocular pressure evaluation performed with contact and non-contact devices. *BMC Ophthalmol.* 2018;18(1):233. <https://doi.org/10.1186/s12886-018-0900-5>
 206. Muriene BJ, Chen ML, Quigley HA, Nguyen TD. The contribution of glycosaminoglycans to the mechanical behaviour of the posterior human sclera. *J R Soc Interface.* 2016;13(119). <https://doi.org/10.1098/rsif.2016.0367>
 207. Kling S, Hafezi F. Corneal biomechanics - a review. *Ophthalmic Physiol Optics.* 2017;37(3):240–52. <https://doi.org/10.1111/opo.12345>.
 208. Boote C, Sigal IA, Grytz R, Hua Y, Nguyen TD, Girard MJA. Scleral structure and biomechanics. *Prog Retin Eye Res.* 2020;74:100773. <https://doi.org/10.1016/j.preteyeres.2019.100773>.
 209. Johannesson G, Hallberg P, Eklund A, Koskela T, Linden C. Change in intraocular pressure measurement after myopic LASEK: a study evaluating goldmann, pascal and applanation resonance tonometry. *J Glaucoma.* 2012;21(4):255–9. <https://doi.org/10.1097/IJG.0b013e31820719c8>.
 210. Shemesh G, Soiberman U, Kurtz S. Intraocular pressure measurements with Goldmann applanation tonometry and dynamic contour tonometry in eyes after IntraLASIK or LASEK. *Clin Ophthalmol.* 2012;6:1967–70. <https://doi.org/10.2147/OPHTH.S38094>.
 211. Barkana Y, Anis S, Liebmann J, Tello C, Ritch R. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. *Arch Ophthalmol.* 2006;124(6):793–7. <https://doi.org/10.1001/archoph.124.6.793>.
 212. Liu JH, Boulligny RP, Kripke DF, Weinreb RN. Nocturnal elevation of intraocular pressure is detectable in the sitting position. *Invest Ophthalmol Vis Sci.* 2003;44(10):4439–42. <https://doi.org/10.1167/iovs.03-0349>.
 213. Leonardi M, Leuenberger P, Bertrand D, Bertsch A, Renaud P. First steps toward noninvasive intraocular pressure monitoring with a sensing contact lens. *Invest Ophthalmol Vis Sci.* 2004;45(9):3113–7. <https://doi.org/10.1167/iovs.04-0015>.
 214. Leonardi M, Pitchon EM, Bertsch A, Renaud P, Mermoud A. Wireless contact lens sensor for intraocular pressure monitoring: assessment on enucleated pig eyes. *Acta Ophthalmol.* 2009;87(4):433–7. <https://doi.org/10.1111/j.1755-3768.2008.01404.x>.
 215. Campigotto A, Leahy S, Zhao G, Campbell RJ, Lai Y. Non-invasive Intraocular pressure monitoring with contact lens. *Br J Ophthalmol.* 2020;104(9):1324–8. <https://doi.org/10.1136/bjophthalmol-2018-313714>.
 216. Chen GZ, Chan IS, Leung LK, Lam DC. Soft wearable contact lens sensor for continuous intraocular pressure monitoring. *Med Eng Phys.* 2014;36(9):1134–9. <https://doi.org/10.1016/j.medengphys.2014.06.005>.
 217. Hsu SH, Chiou JC, Liao YT, et al. An RFID-based on-lens sensor system for long-term IOP monitoring. *Annu Int Conf IEEE*

- Eng Med Biol Soc. 2015;2015:7526–9. <https://doi.org/10.1109/EMBC.2015.7320133>.
218. Xu SC, Gauthier AC, Liu J. The application of a contact lens sensor in detecting 24-hour intraocular pressure-related patterns. *J Ophthalmol.* 2016;2016:4727423. <https://doi.org/10.1155/2016/4727423>.
219. Kouhani MHM, Wu J, Tavakoli A, Weber AJ, Li W. Wireless, passive strain sensor in a doughnut-shaped contact lens for continuous non-invasive self-monitoring of intraocular pressure. *Lab Chip.* 2020;20(2):332–42. <https://doi.org/10.1039/c9lc00735k>.
220. Donida A, Di Dato G, Cunzolo P, et al. A circadian and cardiac intraocular pressure sensor for smart implantable lens. *IEEE Trans Biomed Circuits Syst.* 2015;9(6):777–89. <https://doi.org/10.1109/TBCAS.2015.2501320>.
221. Enders P, Hall J, Bornhauser M, et al. Telemetric intraocular pressure monitoring after boston keratoprosthesis surgery using the eyemate-IO sensor: dynamics in the first year. *Am J Ophthalmol.* 2019;206:256–63. <https://doi.org/10.1016/j.ajo.2019.02.025>.
222. Mihailovic A, Varadaraj V, Ramulu PY, Friedman DS. Evaluating Goldmann applanation tonometry intraocular pressure measurement agreement between ophthalmic technicians and physicians. *Am J Ophthalmol.* 2020;219:170–6. <https://doi.org/10.1016/j.ajo.2020.06.041>.
223. Mansouri K, Gillmann K. Intereye symmetry of 24-hour intraocular pressure-related patterns in untreated glaucoma patients using a contact lens sensor. *J Glaucoma.* 2020;29(8):666–70. <https://doi.org/10.1097/IJG.0000000000001563>.